Paritaprevir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Paritaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively.

Paritaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively; demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50=0.09 to 19 nM), and an EC50 of 0.09 nM against GT4a; The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections.HCV Infection Approved

ABT-450;Veruprevir

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

1216941-48-8

765.88

C40H43N7O7S

>98% (HPLC)

10 mM in DMSO

O=C([C@]([C@]1([H])/C=C\CCCCC[C@@H]2NC(C3=NC=C(C)N=C3)=O)(C1)NC([C@@](C[C@@H](OC4=C5C=CC=CC5=C(C=CC=C6)C6=N4)C7)([H])N7C2=O)=O)NS(=O)(C8CC8)=O

Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16a

(-20℃)

With Ice Pack

≥ 2 years